BioVie

Q: Where is BioVie located?

BioVie's headquarters are located at 680 W Nye Ln Ste 204, Carson City, Nevada, 89703, United States

Q: What is BioVie's phone number?

BioVie's phone number is (775) 888-3162

Q: What is BioVie's official website?

BioVie's official website is www.bioviepharma.com

Q: What is BioVie's Revenue?

BioVie's revenue is <$5 Million

Q: What industry does BioVie belong to?

BioVie is in the industry of: Pharmaceuticals , Healthcare

Q: What technology does BioVie use?

Some of the popular technologies that BioVie uses are: Font Awesome, Bing Ads, PHP, reCAPTCHA

Q: Who is the CEO of BioVie?

BioVie's CEO is Paul Hallenbeck

Q: How do I contact BioVie?

BioVie contact info: Phone number: (775) 888-3162 Website: www.bioviepharma.com

Q: What does BioVie do?

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for... the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada. Read More

Q: What are BioVie social media links?

BioVie Linkedin page BioVie Facebook page BioVie Twitter page

Manufacturing · Nevada, United States · <25 Employees

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascitesdue to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.Read More

View Company Info for Free

Who is BioVie

Headquarters

680 W Nye Ln Ste 204, Carson City, Nevada, 89703, United States

Phone Number

(775) 888-3162

Website

www.bioviepharma.com

Revenue

<$5M

Stock Symbol

BIVI

Industry

Pharmaceuticals

Healthcare

Is this data correct?

View contact profiles from BioVie

Popular SearchesBiovie IncBiovieBiovie CorpBiovie Laboratories IncThe Biovie CoSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: BIVIShow More

BioVie Org Chart

Paul Hallenbeck

Chief Executive Officer

Phone

Wendy K.

Chief Financial Officer

Phone

View Email Formats for BioVie

BioVie Tech Stack

Font Awesome

Bing Ads

Microsoft

PHP

reCAPTCHA

Google

See more technologies

Top Companies in United States

BioVie News & Media

BioVie Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Boston, Massachusetts--(Newsfile Corp. - November 29, 2023) - Block & Leviton is investigating BioVie, Inc. (NASDAQ: BIVI) for potential securities law violations. Investors who have lost money in their BioVie, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/bivi. What is this all about?Before the market opened on November 29, 2023, BioVie, Inc. announced that its Phase 3 trial of NE3107..
Nov 29, 2023
www.newsfilecorp.com
Although BioVie Inc. (NASDAQ:BIVI) insiders have sold lately, they have the highest ownership with 64% stake
Key Insights Insiders appear to have a vested interest in BioVie's growth, as seen by their sizeable ownership 63% of...
Aug 30, 2023
finance.yahoo.com
BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association
CARSON CITY, Nev., June 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract highlighting baseline data from its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s disease will be presented as a poster
Jun 21, 2023
www.globenewswire.com
BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress
CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of NE3107 in the treatment of Parkison’s Disease was presented at the 2023 World Congress on Parkison’s Disease and Relat
May 16, 2023
www.globenewswire.com
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
CARSON CITY, Nev., April 20, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a data abstract from its Phase 2 open label trial evaluating NE7107 in degenerative dementias has been accepted for presentation at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to
Apr 20, 2023
www.globenewswire.com